(1) Regulatory News: THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME eligible), an innovative company specializing in the development of medical equipment for echotherapy treatment, notably for varicose veins, today announces its sales revenues for the year 2020 and roll-out strategy for 2021. Roll-out strategy 2021 SONOVEIN S, the last generation of SONOVEIN systems (CE marking obtained in Oct. 2020), makes SONOVEIN a strong alternative in treatment of varicose veins. It allows faster non-surgical treatment on an ambulatory basis without the need for anaestesia. Since October the company has made significant progress with their roll-out strategy. For 2021, it plans to further expand business development in new territories including Asia. Theraclion will also significantly increase SONOVEIN S installations at new key opinion leader sites. These international experts show strong interest in this distruptive technology. Once equipped, their centers of excellence are the relay of the technology to the rest of the market. SONOVEIN S will then gradually become the gold standard treatment for patients with chronic vein insufficiency.